Search results for " Pharmaceutic"

showing 10 items of 865 documents

Medication adherence and persistence in type 2 diabetes mellitus: perspectives of patients, physicians and pharmacists on the Spanish health care sys…

2017

Elena Labrador Barba,1 Marta Rodríguez de Miguel,1 Antonio Hernández-Mijares,2,3 Francisco Javier Alonso-Moreno,4 Maria Luisa Orera Peña,1 Susana Aceituno,5 María José Faus Dader6 1Department of Medicine, Mylan, Madrid, 2Department of Endocrinology and Nutrition, Doctor Peset University Hospital, Valencia, 3Department of Medicine, University of Valencia, Valencia, 4Department for Primary Health Care, Centro de Salud Sillería, Toledo, 5Outcomes’10, Castellon, 6Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Granada, Granada, Spain Objective: A good relationship between diabetes pa…

medicine.medical_specialtyActivities of daily livingtype 2 diabetes mellitusMedicine (miscellaneous)030209 endocrinology & metabolismLikert scale03 medical and health sciences0302 clinical medicineDiabetes mellitusHealth caremedicine030212 general & internal medicineadherenceAdverse effectPharmacology Toxicology and Pharmaceutics (miscellaneous)Original Researchbusiness.industryHealth PolicyfactorsType 2 Diabetes Mellituspersistencemedicine.diseaseClinical pharmacyPatient Preference and AdherenceFamily medicinestrategiesObservational studybusinessSocial Sciences (miscellaneous)Patient preference and adherence
researchProduct

How to select a biosimilar

2013

In the past few years biosimilars have penetrated the market following the expiry of patents of originator variants. This offers the opportunity to apply high-tech protein products at a lower cost. In contrast to small-molecule generics, clinicians and pharmacists have found it difficult to judge the efficacy and safety profiles of complex protein products. In recent years, the European Medicines Agency (EMA) has gained knowledge on assessing comparability between biosimilars and originator products in scientific and legal areas. This article provides an overview of an extensive set of 31 previously drawn biosimilar selection criteria and describes how several of these criteria are covered …

medicine.medical_specialtyActuarial scienceComplex proteinbusiness.industryAgency (sociology)ComparabilityAlternative medicinemedicineLower costBiosimilarGeneral Pharmacology Toxicology and Pharmaceuticsbusiness
researchProduct

Future perspectives of the pharmacological management of diabetic dyslipidemia

2019

Introduction: Diabetic dyslipidemia is frequent among patients with type 2 diabetes mellitus (T2DM) and is characterized by an increase in triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and small-dense (atherogenic) particles, and by a decrease in low high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) A1 that are strongly related to insulin resistance. The increased flux of free fatty acids from adipose tissue to the liver aggravates hepatic insulin resistance and promotes all of aspects of the dyslipidemic state. Areas covered: Statins are the first-line agents for treatment while other lipid-lowering drugs (ezetimibe, fibrate and proprotein convertase…

medicine.medical_specialtyApolipoprotein Bmedicine.drug_classglucagon like peptide-1 receptor agonist (GLP-1RA)Fibrate030226 pharmacology & pharmacystatins03 medical and health sciences0302 clinical medicineInsulin resistanceEzetimibeInternal medicinemedicineHumansHypoglycemic AgentsPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsOmega 3 fatty acidDyslipidemiasHypolipidemic Agentsfibratebiologybusiness.industrydyslipidemianutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineLipidmedicine.diseasesodium/glucose cotransporter 2 inhibitors (SGLT-2is)LipidsEndocrinologyDiabetes Mellitus Type 2Cardiovascular Diseases030220 oncology & carcinogenesisDipeptidyl peptidase-4 inhibitors (DPP-4is)Dietary Supplementsbiology.proteinKexinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistancebusinessDyslipidemiamedicine.drugezetimibeproprotein convertase subtilisin/kexin type 9 (PCSK9)
researchProduct

Oral local drug delivery and new perspectives in oral drug formulation

2012

Modern pharmaceutical science has provided us with a wide range of substances to be administered with a wide large variety of dosage forms. Local drug delivery systems have been used for a long time; in particular, for the local therapy of diseases affecting the oral cavity. Although these diseases are often extremely responsive to local therapy, the mouth often presents various difficulties in the application of topical compounds (owing to saliva and the mouth's different functions), resulting in a short retention time of dosage forms with a consequent low therapeutic efficacy. To resolve these limitations, research today concentrates on the development of bioadhesive formulations. This re…

medicine.medical_specialtyChemistry PharmaceuticalBioadhesiveAdministration SublingualPharmaceutical Preparations DentalPharmacologyPermeabilityDosage formPathology and Forensic MedicineDrug Delivery SystemsSettore MED/28 - Malattie OdontostomatologicheAdhesivesAdministration MucosalHumansMedicineRadiology Nuclear Medicine and imagingDentistry (miscellaneous)Pharmaceutical sciencesOral mucosaIntensive care medicineDosage Formsbusiness.industryMouth MucosaAdministration BuccalBuccal administrationDrug delivery Buccal mucosa Buccal dosage formsmedicine.anatomical_structureSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliverySurgeryOral SurgerybusinessRetention timeOral retinoid
researchProduct

Compatibility of irinotecan-loaded DC Bead with different volumes and types of non-ionic contrast media.

2015

Objectives Irinotecan-loaded microspheres are used for simultaneous embolisation and chemotherapy of liver metastases of colorectal carcinoma. The aim of the study was to evaluate the compatibility of recently introduced DC Bead M1 (bead size 70–150 µm) loaded with irinotecan after admixture with different types and volumes of non-ionic contrast media over a maximum period of 24 h and storage at room temperature. Methods Test suspensions were prepared by loading 2 mL DC Bead M1 with 100 mg irinotecan within 2 h. The loading efficiency was determined by measuring the concentrations of irinotecan in the excess solutions via a reversed phase high pressure liquid chromatography (RP-HPLC) assay …

medicine.medical_specialtyChromatographyNon ionicChemistryElutionHigh-performance liquid chromatographyMicrosphereSurgeryIrinotecanContrast mediumCompatibility (mechanics)medicineSlurryOriginal ArticleGeneral Pharmacology Toxicology and Pharmaceuticsmedicine.drugEuropean journal of hospital pharmacy : science and practice
researchProduct

What should be the patient's preference regarding the choice of hospital in the case of radical cystectomy? Evaluation of early complications…

2016

Jens Mani,1 Stefan Vallo,1 Maximilian P Brandt,1 Kilian M Gust,1 Claudia Bartsch,1 Johannes Daechert,1 Igor Tsaur,1 Georg Bartsch,2,* Axel Haferkamp1,* 1Department of Urology, Goethe University Hospital, Frankfurt am Main, 2Department of Urology, Johannes Gutenberg University Hospital Mainz, Mainz, Germany *These authors contributed equally to this work Purpose: This study compares early complications after cystectomy and urinary diversion (UD) stratified by the surgical focus and case load of two different department chairpersons in a single institution in two time periods. Creating clear data about complications that can affect the quality of life is an important tool for patient…

medicine.medical_specialtyClavien-Dindo Classificationbusiness.industryHealth Policymedicine.medical_treatmentSignificant differenceUrinary diversion030232 urology & nephrologyMedicine (miscellaneous)University hospitalSurgeryCystectomy03 medical and health sciences0302 clinical medicineVolume settingQuality of lifePatient Preference and Adherence030220 oncology & carcinogenesisMedicinebusinessComplicationPharmacology Toxicology and Pharmaceutics (miscellaneous)Social Sciences (miscellaneous)Patient Preference and Adherence
researchProduct

The Effects of Oregano Oil on Fungal Infections Associated with Metabolic Syndrome

2020

International audience; This study aims to compare the evolution of mycosis associated with metabolic syndrome under allopathic treatment compared to phytotherapy using oregano essential oil. The study was conducted over a period of 6 months, on a total of 72 patients diagnosed with fungal infections associated with metabolic syndrome. The patients were divided into 3 groups, depending on the administered treatment: group 1: 24 patients who received allopathic treatment; group 2: 24 patients who received oregano oil treatment; group 3: control, which did not undergo any antifungal treatment. All three groups were subjected to specific diet therapy for mycosis. The patients were initially ev…

medicine.medical_specialtyDiet therapyItraconazoleMaterials Science (miscellaneous)010402 general chemistry01 natural sciencesGastroenterologyGeneral Biochemistry Genetics and Molecular Biologylaw.inventionFungal infectionsOregano oillawInternal medicineMaterials ChemistrymedicineGeneral Pharmacology Toxicology and PharmaceuticsMycosisProcess Chemistry and TechnologyGeneral EngineeringGeneral ChemistryGeneral Medicinemedicine.disease3. Good health0104 chemical sciencesNystatinTolerabilityMetabolic X syndrome[SDE]Environmental SciencesMetabolic syndromePhytotherapyFluconazolemedicine.drug
researchProduct

Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum

2019

Introduction: Pyoderma gangrenosum (PG) is a noninfectious, reactive inflammatory neutrophilic dermatosis that is commonly associated with autoimmune and neoplastic disorders. There are emerging diagnostic tools and treatment options for PG.Area covered: The diagnosis of PG should be seriously considered when managing ulcers to avoid unnecessary medical and surgical complications with prompt and suitable treatment. There are no standardized treatment guidelines for PG, and current therapy largely depends on the severity and progression of the disease. Systemic corticosteroids, immunosuppressant therapy, and biologic agents remain mainstay therapies. In this article, we present a literature …

medicine.medical_specialtyDiseaseDiagnostic toolsSeverity of Illness Index030226 pharmacology & pharmacySystemic therapyBiological Factors03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesmedicineHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsIntensive care medicineClinical treatmentbusiness.industryGeneral MedicineGold standard (test)medicine.diseasePyoderma GangrenosumBiologic AgentsNeutrophilic dermatosis030220 oncology & carcinogenesisDisease ProgressionDermatologic AgentsbusinessImmunosuppressive AgentsPyoderma gangrenosumExpert Review of Clinical Pharmacology
researchProduct

Unpredictable Performance of pH-Dependent Coatings Accentuates the Need for Improved Predictive in Vitro Test Systems.

2017

First introduced in the second half of the 19th century, enteric coatings are commonly used to protect acid-labile drugs, reduce the risk of gastric side effects due to irritating drugs, or for local drug delivery to the lower gastrointestinal (GI) tract. The currently available enteric-coatings are based on pH-sensitive weakly acidic polymers. Despite the long history of their use, the causes behind their performance often being unpredictable have not been properly investigated with most of the attention being focused only on the gastric emptying. However, little attention has been given to the postgastric emptying disintegration and dissolution of these dosage forms. This lack of attentio…

medicine.medical_specialtyDrug LiberationIn vitro testChemistry PharmaceuticalPharmaceutical SciencePh dependentBiological Availability02 engineering and technologyPharmacologyIn Vitro Techniques030226 pharmacology & pharmacyDosage formBiopharmaceuticsExcipients03 medical and health sciences0302 clinical medicineDrug DiscoveryIntestine SmallmedicineIntensive care medicineGastric emptyingbusiness.industryHydrogen-Ion Concentration021001 nanoscience & nanotechnologyEnteric coatingBioavailabilityDrug LiberationSolubilityDrug deliveryMolecular MedicineTablets Enteric-Coated0210 nano-technologybusinessmedicine.drugMolecular pharmaceutics
researchProduct

Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans.

2020

Abstract Objectives The inter-individual variability of warfarin dosing has been linked to genetic polymorphisms. This study was aimed at performing genotype-driven pharmacokinetic (PK) simulations to predict warfarin levels in Puerto Ricans. Methods Analysis of each individual dataset was performed by one-compartmental modeling using WinNonlin®v6.4. The k e of warfarin given a cytochrome P450 2C9 (CYP2C9) genotype ranged from 0.0189 to 0.0075 h−1. K a and V d parameters were taken from literature. Data from 128 subjects were divided into two groups (i.e., wild-types and carriers) and statistical analyses of PK parameters were performed by unpaired t-tests. Results In the carrier group (n=6…

medicine.medical_specialtyGenotypeCmax030204 cardiovascular system & hematology030226 pharmacology & pharmacyGastroenterologyArticle03 medical and health sciences0302 clinical medicinePharmacokineticsVitamin K Epoxide ReductasesInternal medicineGenotypemedicineHumansPharmacology (medical)DosingGeneral Pharmacology Toxicology and PharmaceuticsCYP2C9GenotypingCytochrome P-450 CYP2C9business.industryWarfarinArea under the curveFarmàcia InvestigacióAnticoagulantsHispanic or LatinoAryl Hydrocarbon HydroxylasesWarfarinbusinessmedicine.drugDrug metabolism and personalized therapy
researchProduct